Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a)
objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment
of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This
will include patients with either previous renal, hepatic, heart, lung, or other solid organ
transplantation or hematopoietic cell transplant and experiencing subsequent documented
locally advanced or metastatic cutaneous malignancies. The study will enroll a total of 65
evaluable patients. Patients will participate up to approximately 3 years including a 28-day
screening period, up to approximately 1 year treatment period, and a 2-year follow-up period.
Phase
Phase 1/Phase 2
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Enrollment Eligibility
Key Inclusion Criteria:
1. Voluntary agreement to provide written informed consent prior to any study procedures
and the willingness and ability to comply with all aspects of the protocol and
understand the risk to their organ allograft.
2. Patients with histologically or cytologically confirmed recurrent, locally advanced or
metastatic (to skin, soft tissue or lymph nodes) cutaneous malignancies, including
CSCC, basal cell carcinoma, Merkel cell carcinoma, and melanoma
3. Patients must have progressed following local resection, prior radiation, topical or
systemic therapies.
4. Documentation from the patient's transplant physician confirming that the patient's
allograft is stable.
5. Patients for whom surgical or radiation treatment of lesions is contraindicated.
6. At least 1 lesion that is measurable and injectable by study criteria (tumor of ≥1cm
in longest diameter or ≥1.5 cm in shortest diameter for lymph nodes).
7. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
8. Anticipated life expectancy > 6 months
9. Baseline ECG without evidence of acute ischemia.
10. All patients must consent to provide archived or newly obtained tumor material (either
formalin-fixed, paraffin-embedded [FFPE] block or 20 unstained slides).
Key Exclusion Criteria:
1. Prior treatment with an oncolytic therapy.
2. Patients with visceral metastases.
3. Patients with active herpetic infections or prior complications of HSV-1 infection
(e.g., herpetic keratitis or encephalitis).
4. Patients with a history of organ graft rejection within 12 months.
5. Had systemic infection requiring intravenous (IV) antibiotics or anti-virals, or other
serious infection within 60 days prior to dosing.
6. Patients who require intermittent or chronic use of systemic (oral or intravenous)
anti-virals with known anti-herpetic activity (e.g., acyclovir) unless for organ
allograft preservation.
7. Patients requiring CTLA-4-Ig medications.
8. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that
required treatment with systemic immunosuppressive treatments beyond that required for
maintenance allograft rejection prevention. The following are not exclusionary:
vitiligo, childhood asthma that has resolved, type 1 diabetes, residual hypothyroidism
that requires only hormone replacement, or psoriasis that does not require systemic
treatment.
9. Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or human
immunodeficiency virus (HIV).
10. Any history of transplant-related viral infections, such as BKV, EBV or CMV, within 3
months of study entry. Patients with a history of hepatitis B or C virus must have
undetectable viral load within 3 months of study entry.
11. Patients with a condition requiring an increase in the patient's usual
immunosuppressive medications within 60 days of study treatment.
12. Known active CNS metastases and/or carcinomatous meningitis.